ArticleESC heart failure2026
Evaluation of LCN2 and miR-8078 as diagnostic biomarkers for congenital heart disease-associated pulmonary arterial hypertension.
Article in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThis study aimed to evaluate the diagnostic value of lipocalin 2 (LCN2) and microRNA-8078 (miR-8078) in congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH).
methodsSeventy-six patients were diagnosed with CHD-PAH according to established clinical guidelines (including mean pulmonary arterial pressure (mPAP), pulmonary artery wedge pressure, and pulmonary vascular resistance) via right heart catheterization. Based on their mPAP, they were stratified into non-PAH (mPAP < 25 mm Hg; n = 28), mild PAH (25 ≤ mPAP < 35 mm Hg; n = 21), and moderate-to-severe PAH (mPAP ≥ 35 mm Hg; n = 27) groups. Plasma LCN2 levels and miR-8078 expression were quantified using Enzyme-linked immunosorbent assay and RT-qPCR, respectively. The diagnostic value was analysed using receiver operating characteristic curves. Correlation analysis assessed associations between biomarkers and hemodynamic parameters. Multi-variate logistic regression identified independent predictors of CHD-PAH.
resultsPlasma LCN2 (135.1 [40.2] vs 67.7 [17.7] ng/ml; P < .05) and relative miR-8078 expression (4.2 ± 1.1 vs 2.3 ± 1.3 fold; P < .05) were significantly elevated in the moderate-to-severe PAH group compared with the non-PAH group. Both markers showed positive correlations with mPAP (LCN2: r = 0.691, P < .001; miR-8078: r = 0.481, P < .001) and pulmonary artery systolic pressure (LCN2: r = 0.579, P < .001; miR-8078: r = 0.391, P < .001). Notably, LCN2 levels positively correlated with miR-8078 expression (r = 0.407, P < .001). For diagnosing moderate-to-severe PAH, the area under the curve (AUC) was 0.883 for LCN2 and 0.749 for miR-8078. The combined model yielded a numerically higher AUC of 0.896, but did not significantly differ from LCN2 alone. Univariate regression analysis identified both LCN2 and miR-8078 as significant predictors of CHD-PAH. LCN2 was identified as an independent risk factor for CHD-PAH.
conclusionPlasma LCN2 and miR-8078 are significantly elevated in patients with CHD-PAH and correlate positively with hemodynamic severity. LCN2, in particular, serves as a robust independent biomarker for the diagnosis and severity assessment of CHD-PAH. Consequently, LCN2 and miR-8078 hold promise as potential non-invasive biomarkers for the diagnosis and severity assessment of CHD-PAH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.